ALB and septic shock: In the recently published Albumin Italian Outcome Sepsis (ALBIOS) study, the administration of 20% HSA as a replacement therapy did not reduce either 28- or 90-day mortality in a population of patients with severe sepsis; however, a subgroup analysis revealed a significant survival benefit among patients with septic shock [31].